Subsets of Idiopathic Inflammatory Myositis Enriched for Contemporaneous Cancer Relative to the General Population

Objective This study investigates cancer risk in idiopathic inflammatory myopathy (IIM) relative to the general population. Methods We conducted a single‐center, retrospective cohort study of IIM patients and malignancy. Myositis‐specific and ‐associated autoantibodies were determined by Euroimmun l...

Full description

Saved in:
Bibliographic Details
Published in:Arthritis & rheumatology (Hoboken, N.J.) N.J.), 2023-04, Vol.75 (4), p.620-629
Main Authors: Mecoli, Christopher A., Igusa, Tak, Chen, Mengkun, Wang, XingYao, Albayda, Jemima, Paik, Julie J., Tiniakou, Eleni, Adler, Brittany, Richardson, Carrie, Kelly, Will, Danoff, Sonye, Mammen, Andrew L., Platz, Elizabeth A., Rosen, Antony, Christopher‐Stine, Lisa, Casciola‐Rosen, Livia, Shah, Ami A.
Format: Article
Language:English
Subjects:
Antibodies
Autoantibodies
Breast cancer
Coenzyme A
Dermatomyositis
Dermatomyositis - epidemiology
Enzymes
Epidemiology
Health risks
Humans
Hydroxymethylglutaryl-CoA reductase
Immunoprecipitation
Inflammation
Inflammatory diseases
Malignancy
Matrix protein
Melanoma
Minority & ethnic groups
Musculoskeletal diseases
Myopathy
Myositis
Neoplasms - epidemiology
Ovarian cancer
Population studies
Proteins
Reductases
Retrospective Studies
Ubiquitin
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective This study investigates cancer risk in idiopathic inflammatory myopathy (IIM) relative to the general population. Methods We conducted a single‐center, retrospective cohort study of IIM patients and malignancy. Myositis‐specific and ‐associated autoantibodies were determined by Euroimmun line blot, enzyme‐linked immunosorbent assay, and immunoprecipitation. We calculated standardized prevalence ratios (SPRs) and adjusted for calendar year, age, sex, race, and ethnicity by comparing observed cancers in IIM patients versus expected cancers in the general population using the Surveillance, Epidemiology, and End Results registry. Results Of 1,172 IIM patients, 203 (17%) patients with a cancer history were studied. Over a median follow‐up of 5.2 years, the observed number of IIM patients diagnosed with cancer was increased 1.43‐fold (SPR 1.43 [95% confidence interval (95% CI) 1.15–1.77]; P = 0.002). Within 3 years of IIM symptom onset, an increased SPR was observed for anti–transcription intermediary factor 1γ (anti‐TIF1γ)–positive patients for ovarian and breast cancer (ovarian SPR 18.39 [95% CI 5.01–47.08], P 
ISSN:2326-5191
2326-5205
2326-5205
DOI:10.1002/art.42311